IER3

1 paper4 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

A gene’s or a process’s line counts the gene with the processes named after it, as NLRP3 with the NLRP3 inflammasome, and the trials of drugs aimed at it.

1 lab in 1 country

Funder: National Natural Science Foundation of China

Animals1

Effects

PARL

downin mice1

1 study

IER3 inhibits PARL in mice.
“IER3 interacted with the presenilin-associated rhomboid-like gene (Parl) and reduced its shear activity”
Animals
IER3 drives the transition from sepsis-associated AKI to CKD by suppressing the mitochondrial translocation of PRDX5
Cellular and molecular life sciences : CMLS8 Dec 2025

Latest

1 in 12 months

Cellular and Molecular Life Sciences8 Dec

IER3 drives the transition from sepsis-associated AKI to CKD by suppressing the mitochondrial translocation of PRDX5

Experiments in miceMitochondrion

Paper

IER3

Effects

Latest

IER3 drives the transition from sepsis-associated AKI to CKD by suppressing the mitochondrial translocation of PRDX5

Related